Promising Lundbeck antidepressant goes into phase II clinical trials  

2006.06.26
Danish pharmaceutical company H. Lundbeck is to enrol 400 patients into a phase II clinical study for its new antidepressant candidate drug Lu AA21004 by the end of Q3 2006

Danish pharmaceutical company H. Lundbeck is to enrol 400 patients into a phase II clinical study for its new antidepressant candidate drug Lu AA21004 by the end of Q3 2006. The decision follows positive pre-clinical results of phase I trials in healthy individuals.

Lu AA21004 is the result of original development work by Lundbeck into a new chemical class of psychotropics, the bis-aryl-sulphanyl amines, the pharmacology of which is said to be markedly different from currently marketed antidepressants. Compared with currently approved antidepressants, preclinical models have demonstrated Lu AA21004 to improve speed of onset of effect as well as efficacy.

"Lu AA 21004 is the result of the efforts of Lundbeck R&D to design and develop novel psychotropics displaying clear-cut improvements in efficacy without compromising patient tolerability and compliance," says Anders Gersel Pedersen, head of Lundbeck Development.

Lundbeck has developed the bis-aryl-sulphanyl amines as a platform for molecular engineering to enable the design of different compounds with different pharmacological mechanisms, so that a range of products can be produced based on the same core molecular structure.

Developing an improved treatment for depression represents a major potential business opportunity for any pharmaceutical company. According to the World Health Organization, an estimated 121 million people worldwide currently suffer from depression. An estimated 5.8% of men and 9.5% of women will experience a depressive episode in any given year. The news was reported by financial daily newspaper Børsen.

Link > Lundbeck 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×